Network-principled deep generative models for designing drug
  combinations as graph sets
  Combination therapy has shown to improve therapeutic efficacy while reducing
side effects. Importantly, it has become an indispensable strategy to overcome
resistance in antibiotics, anti-microbials, and anti-cancer drugs. Facing
enormous chemical space and unclear design principles for small-molecule
combinations, the computational drug-combination design has not seen generative
models to meet its potential to accelerate resistance-overcoming drug
combination discovery. We have developed the first deep generative model for
drug combination design, by jointly embedding graph-structured domain knowledge
and iteratively training a reinforcement learning-based chemical graph-set
designer. First, we have developed Hierarchical Variational Graph Auto-Encoders
(HVGAE) trained end-to-end to jointly embed gene-gene, gene-disease, and
disease-disease networks. Novel attentional pooling is introduced here for
learning disease-representations from associated genes' representations.
Second, targeting diseases in learned representations, we have recast the
drug-combination design problem as graph-set generation and developed a deep
learning-based model with novel rewards. Specifically, besides chemical
validity rewards, we have introduced a novel generative adversarial award,
being generalized sliced Wasserstein, for chemically diverse molecules with
distributions similar to known drugs. We have also designed a network
principle-based reward for drug combinations. Numerical results indicate that,
compared to graph embedding methods, HVGAE learns more informative and
generalizable disease representations. Case studies on four diseases show that
network-principled drug combinations tend to have low toxicity. The generated
drug combinations collectively cover the disease module similar to FDA-approved
drug combinations and could potentially suggest novel systems-pharmacology
strategies.
